Directors buying at Covalon Technologies (V:COV)

Abe Schwartz, a Director and 10% Holder, acquired 114,796 Common Shares on a direct ownership basis at a price of $1.960 through a prospectus or prospectus exempt offering on June 1st, 2017. The insider also acquired 114,796 Warrants with at an exercise price of $2.300 for 3 years. This represents a $225,000 investment into the company's shares and an account share holdings change of 1.4%.

On the same terms, Murray Miller, a Director, acquired 76,531 Common Shares and 76,531 Warrants. This represents a $150,001 investment into the company's shares and an account share holdings change of 15.8%.

Covalon Technologies is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Covalon Technologies Ltd. is a researcher, developer, manufacturer and marketer of medical products that manage patient outcomes and save lives in the areas of wound care, infection management and surgical procedures. The Company offers platform technologies: Collagen matrix; Antimicrobial silicone adhesive and Medical coating technology. The collagen matrix platform is used to manufacture products that treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. The antimicrobial silicone adhesive platform is the basis for a range of pre-surgical, post surgical and vascular access products that are designed to kill any bacteria or yeast that comes into contact with the antimicrobial silicone. The coating technology is a grafting from process, which utilizes photo-polymerization to create active grafting sites.